Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 1.07
AXGN's Cash-to-Debt is ranked lower than
60% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. AXGN: 1.07 )
Ranked among companies with meaningful Cash-to-Debt only.
AXGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: N/A Max: No Debt
Current: 1.07
Equity-to-Asset 0.28
AXGN's Equity-to-Asset is ranked lower than
84% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. AXGN: 0.28 )
Ranked among companies with meaningful Equity-to-Asset only.
AXGN' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.23  Med: 0.74 Max: 0.99
Current: 0.28
-4.23
0.99
Piotroski F-Score: 5
Altman Z-Score: 6.69
Beneish M-Score: -2.42
WACC vs ROIC
1.12%
-90.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -19.25
AXGN's Operating Margin % is ranked lower than
67% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. AXGN: -19.25 )
Ranked among companies with meaningful Operating Margin % only.
AXGN' s Operating Margin % Range Over the Past 10 Years
Min: -1447.95  Med: -94.53 Max: 64.05
Current: -19.25
-1447.95
64.05
Net Margin % -32.05
AXGN's Net Margin % is ranked lower than
71% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. AXGN: -32.05 )
Ranked among companies with meaningful Net Margin % only.
AXGN' s Net Margin % Range Over the Past 10 Years
Min: -1426.03  Med: -127.71 Max: 60.4
Current: -32.05
-1426.03
60.4
ROE % -202.57
AXGN's ROE % is ranked lower than
95% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. AXGN: -202.57 )
Ranked among companies with meaningful ROE % only.
AXGN' s ROE % Range Over the Past 10 Years
Min: -581  Med: -124.68 Max: 264.57
Current: -202.57
-581
264.57
ROA % -39.04
AXGN's ROA % is ranked lower than
75% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. AXGN: -39.04 )
Ranked among companies with meaningful ROA % only.
AXGN' s ROA % Range Over the Past 10 Years
Min: -128.2  Med: -57.42 Max: 173.62
Current: -39.04
-128.2
173.62
ROC (Joel Greenblatt) % -97.97
AXGN's ROC (Joel Greenblatt) % is ranked lower than
69% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. AXGN: -97.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AXGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -35233.33  Med: -277.41 Max: 265933.33
Current: -97.97
-35233.33
265933.33
3-Year Revenue Growth Rate 18.20
AXGN's 3-Year Revenue Growth Rate is ranked higher than
86% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. AXGN: 18.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AXGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -74.3  Med: 3.4 Max: 471.3
Current: 18.2
-74.3
471.3
3-Year EBITDA Growth Rate -28.90
AXGN's 3-Year EBITDA Growth Rate is ranked lower than
90% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. AXGN: -28.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AXGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -47.9  Med: -11.1 Max: 197.7
Current: -28.9
-47.9
197.7
3-Year EPS without NRI Growth Rate -24.20
AXGN's 3-Year EPS without NRI Growth Rate is ranked lower than
79% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. AXGN: -24.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AXGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.5  Med: -6.7 Max: 259.3
Current: -24.2
-50.5
259.3
GuruFocus has detected 4 Warning Signs with AxoGen Inc $AXGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AXGN's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

AXGN Guru Trades in Q2 2016

Jim Simons 174,700 sh (New)
» More
Q3 2016

AXGN Guru Trades in Q3 2016

Chuck Royce 20,000 sh (New)
Jim Simons 126,900 sh (-27.36%)
» More
Q4 2016

AXGN Guru Trades in Q4 2016

Jim Simons Sold Out
Chuck Royce Sold Out
» More
Q1 2017

AXGN Guru Trades in Q1 2017

Jim Simons 140,951 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with AXGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 334510    SIC: 3845
Compare:NYSE:IVC, NAS:EXAC, NAS:TCMD, NAS:ELOS, NYSE:CRY, NAS:GNMK, NAS:VRAY, NAS:ARAY, NAS:XENT, OTCPK:CSRMY, NAS:RTIX, NAS:CUTR, OTCPK:XVIPF, NAS:OFIX, AMEX:CVRS, OTCPK:IPDQF, NAS:OBLN, NAS:FONR, NAS:VIVE, OTCPK:DMTRF » details
Traded in other countries:LT3.Germany,
Headquarter Location:USA
AxoGen Inc is a medical technology company dedicated to peripheral nerve repair. It provide products and education to improve surgical treatment algorithms for peripheral nerve injuries.

AxoGen Inc is a regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves the Company has developed and licensed technologies which are used in its products. Its product portfolio includes Avance Nerve Graft, which the Company believes is the first and only commercially available processed allograft nerve for bridging nerve discontinuities. AxoGuard Nerve Connector, is used as a coaptation aid to facilitate the tensionless repair of severed nerves, and AxoGuard Nerve Protector is used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. The Company's products are used by surgeons during surgical interventions to repair a wide variety of nerve injuries throughout the body. These injuries range from a simple laceration of a finger to a complex brachial plexus injury (an injury to the network of nerves that originate in the neck) as well as nerve injuries caused by dental and other surgical procedures. Avance Nerve Graft provides surgeons bridging material with the micro-architecture of a human nerve. This structure is essential and allows for bridging nerve gaps or discontinuities up to 70mm in length. Additionally, Avance Nerve Graft has product and sales synergies with AxoGuard Nerve Protector and AxoGuard Nerve Connector. AxoGuard products provide the unique features of pliability, suturability, and translucence for visualization of the underlying nerve, while also allowing the patient's own cells to incorporate into the extracellular matrix to remodel and form a tissue similar to the outermost layer of the nerve (nerve epineurium). Regenerative medical products enable the repair, restoration, replacement or regeneration of tissue or organ systems of the body. Regenerative medical products are becoming common in various medical arenas because they have been shown to be effective repairing injured or defective tissues, such as bone, tendons, dermis and other tissues of the body. AxoGen's products are subject to regulation by the FDA, as well as other federal and state regulatory bodies in the U.S. and comparable authorities in other countries.

Top Ranked Articles about AxoGen Inc

AxoGen, Inc. to Present at the Jefferies Global Healthcare Conference
AxoGen, Inc. to Report First Quarter 2017 Financial Results and Host Conference Call on Thursday, May 4, 2017
AxoGen, Inc. Announces 2017 Annual Shareholders’ Meeting
AxoGen, Inc. to Present at the Oppenheimer 27th Annual Healthcare Conference
ALACHUA, Fla., March 07, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, President and Chief Executive Officer, will present at the Oppenheimer 27th Annual Healthcare Conference in New York City, NY, at The Westin New York Grand Central. The presentation is scheduled for Tuesday, March 21, 2017 at 1:35 p.m. ET.
The presentation will be webcast live and can be accessed through the Investors page at www.axogeninc.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.axogeninc.com.About AxoGen, Inc.
AxoGen (NASDAQ:AXGN) is a global leader in innovative surgical solutions for peripheral nerve injuries. AxoGen's portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, and Avive™ Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed. Along with these core surgical products, AxoGen also offers AcroVal™ Neurosensory & Motor Testing System and AxoTouch™ Two-Point Discriminator. These evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "projects," "forecasts," "continue," "may," "should," "will," and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our assessment on our internal control over financial reporting, our growth, our 2017 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
[email protected]

The Trout Group – Investor Relations
Brian Korb
646.378.2923
[email protected]

Read more...
AxoGen, Inc. to Present at Upcoming Investor Conferences
29th Annual ROTH Conference, March 13
Canaccord Genuity Musculoskeletal Conference, March 14ALACHUA, Fla. , March 02, 2017 (GLOBE NEWSWIRE) -- AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, President and Chief Executive Officer, will present at two upcoming investor conferences.Ms. Zaderej will present at the 29th Annual ROTH Conference in Dana Point, CA at the Ritz Carlton. The presentation is scheduled for Monday, March 13 at 1:30 p.m. PT (4:30 p.m. ET). She will also present at the Canaccord Genuity Musculoskeletal Conference at the Westin San Diego in San Diego, CA on March 14 at 11:30 a.m. PT (2:30 p.m. ET).The presentations will be webcast live and can be accessed through the Investors page at www.axogeninc.com. For those not available to listen to the live broadcasts, replays will be archived for 90 days and available through the Investors page on www.axogeninc.com. About AxoGen, Inc.
AxoGen (NASDAQ:AXGN) is a global leader in innovative surgical solutions for peripheral nerve injuries. AxoGen's portfolio of products includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves, AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments, and Avive™ Soft Tissue Membrane, a minimally processed human umbilical cord membrane that may be used as a resorbable soft tissue covering to separate tissue layers and modulate inflammation in the surgical bed. Along with these core surgical products, AxoGen also offers AcroVal™ Neurosensory & Motor Testing System and AxoTouch™ Two-Point Discriminator. These evaluation and measurement tools assist health care professionals in detecting changes in sensation, assessing return of sensory, grip, and pinch function, evaluating effective treatment interventions, and providing feedback to patients on nerve function. The AxoGen portfolio of products is available in the United States, Canada, the United Kingdom, and several other European and international countries.Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "projects," "forecasts," "continue," "may," "should," "will," and variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our assessment on our internal control over financial reporting, our growth, our 2017 guidance, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Contacts:
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
[email protected]

The Trout Group – Investor Relations                                             
Brian Korb
646.378.2923
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 41.96
AXGN's PB Ratio is ranked lower than
98% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. AXGN: 41.96 )
Ranked among companies with meaningful PB Ratio only.
AXGN' s PB Ratio Range Over the Past 10 Years
Min: 0.69  Med: 13.37 Max: 607.5
Current: 41.96
0.69
607.5
PS Ratio 10.71
AXGN's PS Ratio is ranked lower than
79% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. AXGN: 10.71 )
Ranked among companies with meaningful PS Ratio only.
AXGN' s PS Ratio Range Over the Past 10 Years
Min: 0.48  Med: 4.75 Max: 833.33
Current: 10.71
0.48
833.33
EV-to-EBIT -58.29
AXGN's EV-to-EBIT is ranked lower than
99.99% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. AXGN: -58.29 )
Ranked among companies with meaningful EV-to-EBIT only.
AXGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -84  Med: -7.3 Max: 4.9
Current: -58.29
-84
4.9
EV-to-EBITDA -61.62
AXGN's EV-to-EBITDA is ranked lower than
99.99% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. AXGN: -61.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
AXGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -93  Med: -7.5 Max: 7.6
Current: -61.62
-93
7.6
Current Ratio 3.82
AXGN's Current Ratio is ranked higher than
73% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. AXGN: 3.82 )
Ranked among companies with meaningful Current Ratio only.
AXGN' s Current Ratio Range Over the Past 10 Years
Min: 0.23  Med: 4.46 Max: 78.49
Current: 3.82
0.23
78.49
Quick Ratio 3.28
AXGN's Quick Ratio is ranked higher than
76% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. AXGN: 3.28 )
Ranked among companies with meaningful Quick Ratio only.
AXGN' s Quick Ratio Range Over the Past 10 Years
Min: 0.12  Med: 3.28 Max: 78.49
Current: 3.28
0.12
78.49
Days Inventory 267.67
AXGN's Days Inventory is ranked lower than
81% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. AXGN: 267.67 )
Ranked among companies with meaningful Days Inventory only.
AXGN' s Days Inventory Range Over the Past 10 Years
Min: 251.85  Med: 275.52 Max: 489.83
Current: 267.67
251.85
489.83
Days Sales Outstanding 67.65
AXGN's Days Sales Outstanding is ranked lower than
52% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. AXGN: 67.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
AXGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.47  Med: 62.74 Max: 365
Current: 67.65
0.47
365
Days Payable 152.71
AXGN's Days Payable is ranked higher than
74% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. AXGN: 152.71 )
Ranked among companies with meaningful Days Payable only.
AXGN' s Days Payable Range Over the Past 10 Years
Min: 123.12  Med: 176.67 Max: 256.21
Current: 152.71
123.12
256.21

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -23.90
AXGN's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. AXGN: -23.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AXGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -59  Med: -1.1 Max: 1.1
Current: -23.9
-59
1.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 51.33
AXGN's Price-to-Net-Current-Asset-Value is ranked lower than
88% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 6.88 vs. AXGN: 51.33 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AXGN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 6.85 Max: 229.33
Current: 51.33
0
229.33
Price-to-Tangible-Book 45.29
AXGN's Price-to-Tangible-Book is ranked lower than
93% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. AXGN: 45.29 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AXGN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.76  Med: 2.97 Max: 903
Current: 45.29
0.76
903
Price-to-Median-PS-Value 2.25
AXGN's Price-to-Median-PS-Value is ranked lower than
83% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. AXGN: 2.25 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AXGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.6 Max: 120
Current: 2.25
0
120
Earnings Yield (Greenblatt) % -1.72
AXGN's Earnings Yield (Greenblatt) % is ranked lower than
65% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. AXGN: -1.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AXGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1.79  Med: 234.1 Max: 6116
Current: -1.72
-1.79
6116
Forward Rate of Return (Yacktman) % -30.63
AXGN's Forward Rate of Return (Yacktman) % is ranked lower than
99.99% of the 125 Companies
in the Global Medical Devices industry.

( Industry Median: 8.85 vs. AXGN: -30.63 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AXGN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -51.1  Med: -5.2 Max: 25.8
Current: -30.63
-51.1
25.8

More Statistics

Revenue (TTM) (Mil) $45.24
EPS (TTM) $ -0.46
Beta-0.39
Short Percentage of Float5.27%
52-Week Range $5.30 - 16.00
Shares Outstanding (Mil)33.10

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 58 80 107
EPS ($) -0.35 -0.10 0.11
EPS without NRI ($) -0.35 -0.10 0.11
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AXGN

Headlines

Articles On GuruFocus.com
AxoGen, Inc. to Present at the Jefferies Global Healthcare Conference May 23 2017 
AxoGen, Inc. to Report First Quarter 2017 Financial Results and Host Conference Call on Thursday, Ma Apr 14 2017 
AxoGen, Inc. Announces 2017 Annual Shareholders’ Meeting Apr 07 2017 
AxoGen, Inc. to Present at the Oppenheimer 27th Annual Healthcare Conference Mar 07 2017 
AxoGen, Inc. to Present at Upcoming Investor Conferences Mar 02 2017 
AxoGen, Inc. CMO Jill Schiaparelli and Oral Maxillofacial Surgeon Dr. Shahrokh Bagheri to Discuss Ne Jan 09 2015 
Weekly CFO Buys Highlight: AxoGen Inc, Medley Capital Corp, Quantum Fuel Systems Technologies Worldw Dec 20 2014 
AxoGen, Inc. CEO Karen Zaderej to Be Interviewed on Clear Channel -- iHeart Business Talk Radio's "T Dec 02 2014 

More From Other Websites
AxoGen, Inc. to Present at the Jefferies Global Healthcare Conference May 23 2017
AxoGen (AXGN) Shows Strength: Stock Adds 6.1% in Session May 22 2017
ETFs with exposure to AxoGen, Inc. : May 15, 2017 May 15 2017
AxoGen, Inc. :AXGN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017 May 10 2017
AxoGen reports 1Q loss May 04 2017
AxoGen, Inc. Reports 2017 First Quarter Financial Results May 04 2017
Investor Network: AxoGen, Inc. to Host Earnings Call May 04 2017
ETFs with exposure to AxoGen, Inc. : April 17, 2017 Apr 17 2017
AxoGen, Inc. to Report First Quarter 2017 Financial Results and Host Conference Call on Thursday,... Apr 14 2017
Cramer Remix: Why a slew of IPOs might not be a good thin... Apr 11 2017
AxoGen, Inc. Announces 2017 Annual Shareholders’ Meeting Apr 07 2017
AxoGen, Inc. breached its 50 day moving average in a Bullish Manner : AXGN-US : April 3, 2017 Apr 03 2017
AxoGen, Inc. :AXGN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Mar 17 2017
AxoGen, Inc. :AXGN-US: Earnings Analysis: 2016 By the Numbers : March 10, 2017 Mar 10 2017
AxoGen, Inc. to Present at the Oppenheimer 27th Annual Healthcare Conference Mar 07 2017
AxoGen, Inc. breached its 50 day moving average in a Bearish Manner : AXGN-US : March 6, 2017 Mar 06 2017
AxoGen, Inc. to Present at Upcoming Investor Conferences Mar 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)